Krystal Biotech, Inc. $KRYS Shares Sold by C WorldWide Group Holding A S

C WorldWide Group Holding A S reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,809 shares of the company’s stock after selling 18,000 shares during the quarter. C WorldWide Group Holding A S’s holdings in Krystal Biotech were worth $17,516,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Greenline Wealth Management LLC bought a new position in Krystal Biotech in the 4th quarter valued at about $34,000. Sound Income Strategies LLC raised its position in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares in the last quarter. UMB Bank n.a. raised its position in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares in the last quarter. Global Retirement Partners LLC lifted its stake in shares of Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after acquiring an additional 142 shares during the period. Finally, Danske Bank A S bought a new position in shares of Krystal Biotech in the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $341.79 on Friday. The stock has a market capitalization of $10.08 billion, a P/E ratio of 45.69 and a beta of 0.50. Krystal Biotech, Inc. has a 1 year low of $130.50 and a 1 year high of $382.54. The business’s fifty day moving average is $330.40 and its two-hundred day moving average is $289.01.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, research analysts forecast that Krystal Biotech, Inc. will post 7.41 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last ninety days. 13.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several recent analyst reports. Bank of America boosted their target price on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday. Evercore restated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 5th. HC Wainwright raised their target price on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Finally, Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $360.67.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.